Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 3.99B |
| Revenue (ttm) | 7.70M |
| Net Income (ttm) | -465.32M |
| Shares Out | 104.71M |
| EPS (ttm) | -4.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,678,921 |
| Open | 39.41 |
| Previous Close | 38.62 |
| Day's Range | 37.49 - 40.00 |
| 52-Week Range | 25.83 - 57.99 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 76.75 (+101.18%) |
| Earnings Date | May 7, 2026 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price target is $76.75, which is an increase of 101.18% from the latest price.
News
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medica...
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the...
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health S...
Crinetics Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted a strong commercial launch for PALSONIFY, robust clinical pipeline progress, and positive payer dynamics. Key milestones include phase 3 trials for carcinoid syndrome and CAH, a positive EU regulatory outlook, and sustained funding into 2030.
Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 marked a pivotal year with the successful U.S. launch of PALSONIFY, strong early uptake, and expanding payer coverage. Robust financials, a $1.4B cash position, and advancing late-stage pipeline position the company for continued growth and innovation.
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, Februar...
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investig...
Crinetics Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant progress was made with the approval and launch of Palsinify, strong early revenue, and broad prescriber adoption. The pipeline advanced with positive atumelnant data and new clinical programs, supported by $1.4 billion in funding and a clear strategy for long-term growth.
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-q...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Transcript: Study Update
Palsonify's launch saw strong early adoption, broad prescriber engagement, and rapid payer coverage, generating over $5 million in first-quarter revenue. Atumelnant's phase II and OLE data show robust, sustained androgen reduction and favorable safety, supporting high confidence in the ongoing phase III Calm-CAH trial.
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (8...
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30...
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will pr...
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH Phase 3 study builds on positive phase 2 results showing ...
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with...
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community...
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-...
Crinetics Pharmaceuticals Earnings Call Transcript: Q3 2025
Strong early launch for Palsanafy with rapid patient uptake, positive prescriber and payer feedback, and robust community engagement. Q3 saw increased R&D and SG&A expenses, with a $1.1B cash position supporting operations into 2029. Pipeline progress continues in CAH and oncology.
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway in...
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effect...